Oncology Clinical Trial Design Planning Based on a Multistate Model That Jointly Models Progression‐Free and Overall Survival Endpoints
Biometrical Journal · 2025
DOI: 10.1002/bimj.70017 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biometrical Journal, 2025. Verfasst von Alexandra Erdmann und 2 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Statistics, Ulm University, Ulm, Germany. Hauptthemen laut MEDLINE: Clinical Trials as Topic, Models, Statistical, Biometry, Progression-Free Survival. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: German Research Foundation, Deutsche Forschungsgemeinschaft.
Abstract (Originalsprache)
When planning an oncology clinical trial, the usual approach is to assume proportional hazards and even an exponential distribution for time‐to‐event endpoints. Often, besides the gold‐standard endpoint overall survival (OS), progression‐free survival (PFS) is considered as a second confirmatory endpoint. We use a survival multistate model to jointly model these two endpoints and find that neither exponential distribution nor proportional hazards will typically hold for both endpoints simultaneously. The multistate model provides a stochastic process approach to model the dependency of such endpoints neither requiring latent failure times nor explicit dependency modeling such as copulae. We use the multistate model framework to simulate clinical trials with endpoints OS and PFS and show how design planning questions can be answered using this approach. In particular, nonproportional hazards for at least one of the endpoints are a consequence of OS and PFS being dependent and are naturally modeled to improve planning. We then illustrate how clinical trial design can be based on simulations from a multistate model. Key applications are coprimary endpoints and group‐sequential designs. Simulations for these applications show that the standard simplifying approach may very well lead to underpowered or overpowered clinical trials. Our approach is quite general and can be extended to more complex trial designs, further endpoints, and other therapeutic areas. An R package is available on CRAN.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Institute of Statistics, Ulm University, Ulm, Germany.
- Product Development Data Sciences, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
ORCID-Profile: Alexandra Erdmann, Jan Beyersmann
Förderung
- German Research Foundation
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Erdmann, A., Beyersmann, J., & Rufibach, K. (2025). Oncology Clinical Trial Design Planning Based on a Multistate Model That Jointly Models Progression‐Free and Overall Survival Endpoints. Biometrical Journal. https://doi.org/10.1002/bimj.70017
Vancouver
Erdmann A, Beyersmann J, Rufibach K. Oncology Clinical Trial Design Planning Based on a Multistate Model That Jointly Models Progression‐Free and Overall Survival Endpoints. Biometrical Journal. 2025. doi:10.1002/bimj.70017
BibTeX
@article{Erdmann2025,
author = {Erdmann, Alexandra and Beyersmann, Jan and Rufibach, Kaspar},
title = {Oncology Clinical Trial Design Planning Based on a Multistate Model That Jointly Models Progression‐Free and Overall Survival Endpoints},
journal = {Biometrical Journal},
year = {2025},
doi = {10.1002/bimj.70017}
}
EUVIMED